The moves come as Bayer seeks approval from Berkeley leaders for a new 30-year master plan that would allow the Germany-based company to build 1 million square feet of production, research and office space and add some 1,000 employees over that period.
At the forefront of Bayer's big plans are cell therapies, which employ genetically engineered cells to fix blood cancers and potentially more diseases, and one-shot-and-done gene therapies that insert a correct copy of a gene to replace a defective, disease-causing gene.
By The Francis Crick Institute, Press Release | 04.09.2021
Researchers at the Francis Crick Institute have revealed that CRISPR-Cas9 genome editing can lead to unintended mutations at the targeted section of DNA in early human embryos. The work highlights the need for greater awareness of and further research into...
Gene editing causes drastic unwanted effects in gene-edited plants including severe deformities, a new scientific publication in the journal Environmental Sciences Europe shows. This is the case even when the changes are intended by...
By Gina Maranto, Biopolitical Times guest contributor | 04.05.2021
It’s not for nothing that Time, Inc. developed its formula for telling stories—catchy lede, billboard that tells 'em what you’re going to tell ‘em, last graf that catapults them into the future. No wobbling; narrative charging right along. In the rush, the reader is propelled, questions cast aside, riding the tale you want them to believe.
Not surprisingly, Walter Isaacson, bestselling author and former Time editor, has the style down pat. A sometimes breathless, technocratic enthusiasm; an ability to reduce...